Analyzing Terumo (OTCMKTS:TRUMY) and Vivos Therapeutics (NASDAQ:VVOS)

Vivos Therapeutics (NASDAQ:VVOS) and Terumo (OTCMKTS:TRUMY) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Volatility and Risk

Vivos Therapeutics has a beta of 6.04, indicating that its share price is 504% more volatile than the S&P 500. Comparatively, Terumo has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Vivos Therapeutics and Terumo, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
Terumo	0	1	0	1	3.00

Vivos Therapeutics presently has a consensus price target of $2.80, suggesting a potential upside of 1,402.15%. Given Vivos Therapeutics’ higher probable upside, research analysts clearly believe Vivos Therapeutics is more favorable than Terumo.

Profitability

This table compares Vivos Therapeutics and Terumo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Terumo	13.83%	10.55%	7.42%

Insider & Institutional Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Vivos Therapeutics and Terumo”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	0.15	-$21.17 million	($1.90)	-0.10
Terumo	$7.52 billion	3.04	$897.03 million	$0.71	21.83

Terumo has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Terumo, indicating that it is currently the more affordable of the two stocks.

Summary

Terumo beats Vivos Therapeutics on 10 of the 15 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.